



IFW

Patent Application  
Attorney Docket No. PC25367A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 7th day of June 2004

By

*Irene Grantham*  
(Signature of person mailing)  
Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David Hepworth :

APPLICATION NO.: 10/800,065 : Examiner: To Be Assigned

FILING DATE: March 12, 2004 : Group Art Unit: To Be Assigned

TITLE: 3(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic Acid  
Derivatives as NEP Inhibitors :

Mail Stop Amendment

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: June 7, 2004  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof  
Martha G. Munchhof  
Attorney for Applicant(s)  
Reg. No. 47,811



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25367A	SERIAL NO. 10/800,065
	APPLICANT David Hepworth	
	FILING DATE March 12, 2004	GROUP To Be Assigned

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	2	5	0	3	0	5	9	4/4/50	Miescher et al.	260	309.6	
	US	2	5	9	9	0	0	0	6/3/52	Kerwin, et al.	260	570.7	
	US	3	3	8	1	0	0	9	4/30/68	Palazzo, et al.	260	268	
	US	3	5	1	1	8	3	6	5/12/70	Hess, et al.	260	256.4	
	US	3	5	2	7	7	6	1	9/8/70	Archibald, et al.	260	293	
	US	3	9	9	7	6	6	6	12/14/76	Witte, et al.	424	250	
	US	4	0	2	6	8	9	4	5/31/77	Winn, et al.	260	256.4Q	
	US	4	1	8	8	3	9	0	2/12/80	Campbell	424	251	
	US	4	2	5	2	7	2	1	2/24/81	Silvestrini, et al.	260	243.3	
	US	4	3	1	5	0	0	7	2/9/82	Manoury	424	251	
	US	4	7	0	3	0	6	3	12/27/87	Imai, et al.	514	603	
	US	4	7	2	7	1	5	4	2/23/88	Papenfuhs	548	150	
	US	5	5	7	6	3	2	2	11/19/96	Takase, et al.	514	260	
	US	6	6	9	4	5	6	8	12/16/97	Onoda, et al.	514	267	
	US	6	0	3	7	3	4	6	3/14/00	Doherty, et al.	514	258	
	US	6	1	0	6	8	6	4	8/22/00	Dolan, et al.	424	488	

### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	5	1	0	7	3	9	5	5/30/91	PCT	C07C	323/59		
	WO	9	1	1	0	6	4	4	7/25/91	PCT	C07C	237/24		
	WO	9	1	1	1	1	7	2	8/8/91	PCT	A61K	9/00		
	WO	9	3	3	7	1	4	3	4/15/93	PCT	C07D	487/04		
	WO	9	4	3	0	1	5	3	1/6/94	PCT	C08D	473/30		
	WO	5	4	3	2	5	4	5	2/3/94	PCT	C08B	37/16		
	WO	9	4	0	5	6	6	1	3/17/94	PCT	C07D	471/04		
	WO	9	5	1	9	9	7	8	7/27/95	PCT	C07D	471/14		

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						ATTY. DOCKET NO. PC25367A				SERIAL NO. 10/800,065				
						APPLICANT David Hepworth								
						FILING DATE March 12, 2004				GROUP To Be Assigned				
	WO	9	8	4	9	1	6	6	11/5/98	PCT	C07D	487/04		
	WO	9	8	5	6	1	4	8	12/10/98	PCT	A61K	47/48		
	WO	9	9	0	2	1	5	9	1/21/99	PCT	A61K	31/495		
	WO	9	9	2	1	1	3	3	5/20/99	PCT	C07D	487/04		
	WO	9	9	3	2	6	6	7	6/24/99	PCT	A61K	31/00		
	WO	9	5	6	4	9	6	8	10/28/99	PCT	C07K	14/68		
	WO	9	6	5	4	3	3	3	10/28/99	PCT	C07D	487/04		
	WO	9	9	6	0	6	7	2	12/16/99	PCT	A61K	31/47		
	WO	9	6	6	4	4	0	2	12/16/99	PCT	A61K	31/535		
	WO	0	0	6	2	6	5	0	1/20/00	PCT	A61K	31/00		
	WO	9	9	5	5	6	7	9	11/4/99	PCT	C07D	217/04		
	WO	0	0	1	2	4	7	5	3/9/00	PCT	A61K	31/13		
	WO	0	0	2	3	0	5	6	4/27/00	PCT	A61K	31/00		
	WO	0	0	2	1	7	4	5	5/4/00	PCT	C07D	487/04		
	WO	0	0	2	4	5	9	3	5/25/00	PCT	A61K	31/495		
	WO	0	0	4	0	2	2	6	7/13/00	PCT	A61K	31/00		
	WO	0	6	5	8	3	6	1	10/5/00	PCT	C07K	14/68		
	WO	0	6	7	4	5	7	9	12/14/00	PCT	A61K	31/445		
	WO	0	1	0	5	4	0	1	1/25/01	PCT	A61K	31/4184		
	WO	0	4	1	3	4	1	2	2/22/01	PCT	G01N	33/53		
	WO	0	1	1	4	4	7	9	3/1/01	PCT	G01N	33/53		
	WO	0	1	2	7	1	1	8	4/19/01	PCT	C07D	487/04		
	WO	0	1	2	7	4	1	3	4/19/01	PCT	C07D	487/04		
	WO	0	1	4	7	1	9	5	7/5/01	PCT	A61K	9/14		
	WO	0	2	0	2	5	1	3	1/10/02	PCT	C07C	237/22		
	WO	0	2	0	3	9	9	5	1/17/02	PCT	A61K	31/55		
	WO	0	2	7	9	1	4	3	10/10/02	PCT	C07C	235/82		
	WO	0	2	9	0	4	4	3	11/14/02	PCT	C09B	49/00		
	EP	0	4	6	3	7	5	6	1/2/92	EP	C07D	487/04		

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC25367A		SERIAL NO. 10/800,065			
										APPLICANT David Hepworth					
										FILING DATE March 12, 2004		GROUP To Be Assigned			
	EP	0	5	2	6	0	0	4	2/3/93	EP	C07D	487/04			
	EP	0	9	9	5	7	5	0	4/26/00	EP	C07D	487/04			
	EP	0	9	9	5	7	5	1	4/26/00	EP	C07D	487/04			
	EP	1	0	9	7	7	1	0	5/9/01	EP	A61K	38/55			
	EP	1	2	5	8	4	1	1	11/20/02	EP	C07C	235/40			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
			Finnin, et al., "Transdermal Penetration Enhancers: Applications, Limitations, and Potential", <u>Journal of Pharm. Sci.</u> <b>88</b> (10), pp. 955-958 (1999)												
			Berman, et al., "Femal Sexual Dysfunction: Incidence, Pathophysiology, Evaluation, and Treatment Options", <u>Urology</u> <b>54</b> , pp. 385-391 (1999)												
			Rotella, et al., "N-3-Substituted Imidzoquinazonones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction", <u>J. Med. Chem.</u> <b>43</b> , pp. 1257-1263 (2000)												
			Carrier, et al., "Erectile Dysfunction", <u>Clinical Andrology</u> <b>23</b> (4), pp. 773-782 (1994)												
			Feldman, et al., "Impotence and its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study", <u>The Journal of Urology</u> <b>151</b> , pp. 54-61 (1994)												
			Park, et al., "Vasculogenic Female Sexual Dysfunction: The Hemodynamic Basis for Vaginal Engorgement Insufficiency and Clitoral Erectile Insufficiency", <u>International Journal of Impotence Research</u> <b>9</b> , pp. 27-37 (1997)												
			Goldstein, et al., "Vasculogenic Female Sexual Dysfunction: Vaginal Engorgement and Clitoral Erectile Insufficiency Syndromes", <u>International Journal of Impotence Research</u> <b>10</b> (Suppl. 2), pp. S84-S90 (1998)												
			Leilblum, "Definition and Classification of Female Sexual Disorders", <u>International Journal of Impotence Research</u> <b>10</b> (Suppl. 2), pp. S104-S106 (1998)												
			Chemler, et al., "The B-alkyl Suzuki-Miyaura Cross-Coupling Reaction: A Versatile C-C Bond-Forming Tool", <u>Angew. Chemie Int. Ed.</u> <b>40</b> , pp. 4544-4568 (2001)												
			Johnson, et al., "Syntheses of (Z)- and (E)-4-Amino-2-(trifluoromethyl)-2-butenic Acid and Their Inactivation of $\chi$ -Aminobutyric Acid Aminotransferase", <u>Bioorg. &amp; Med. Chem.</u> <b>7</b> , pp. 1625-1636 (1999)												
			Beilenson, et al., "5-Chloro- and 5-Bromo-1-methylbenzthiazole and Cyanine Dyes Prepared from them", <u>J. Chem. Soc.</u> , pp. 1225-1231 (1936)												
			Haleblian, "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications", <u>Journal of Pharmaceutical Sciences</u> <b>64</b> (8), pp. 1269-1288 (1975)												
			Booth, et al., "A Rapid Method for the Preparation of Microvilli from Rabbit Kidney", <u>Biochem. J.</u> <b>142</b> , pp. 575-581 (1974)												
			Bublielmetty, et al., "Synthèse et quaternisation de bases benzothiazoliques en vue de l'obtention de composés spiropyraniques diversement substitué", <u>Bull. Soc. Chim. France</u> <b>8</b> , pp. 2812-2823 (1967)												
			Liang, et al., "Fast-dissolving Intraoral Drug Delivery Systems", <u>Exp. Opin. Ther. Patents</u> <b>11</b> (6), pp. 981-986 (2001)												
			Verma, et al., "Current Status of Drug Delivery Technologies and Future Directions", <u>Pharm. Tech. On-line</u> <b>25</b> (2), pp. 1-14 (2001)												
EXAMINER			DATE CONSIDERED												

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. PC25367A	SERIAL NO. 10/800,065
	APPLICANT David Hepworth	
	FILING DATE March 12, 2004	GROUP To Be Assigned
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>		

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE